Association study of methylenetetrahydrofolate reductase genetic polymorphism C677T with extrapyramidal side effects of antipsychotic treatment

2018 ◽  
Author(s):  
Tatiana Zhilyaeva
Keyword(s):  
Genetic Polymorphism ◽  
Side Effects ◽  
Association Study ◽  
Methylenetetrahydrofolate Reductase ◽  
Antipsychotic Treatment ◽  
Extrapyramidal Side Effects

Association of MTHFR 677C > T genetic polymorphism with extrapyramidal side effects of antipsychotic treatment

Gene Reports ◽  
2020 ◽  
Vol 20 ◽  
pp. 100717
Author(s):  
T.V. Zhilyaeva ◽  
E.V. Akimova ◽  
A.V. Sergeeva ◽  
A.S. Blagonravova ◽  
G.E. Mazo
Keyword(s):  
Genetic Polymorphism ◽  
Side Effects ◽  
Antipsychotic Treatment ◽  
Extrapyramidal Side Effects

Antipsychotic treatment in older schizophrenia patients with extrapyramidal side effects in Asia (2001 – 2009)

2012 ◽  
Author(s):  
Yu-Tao Xiang ◽  
Julie Kreyenbuhl ◽  
Faith B. Dickerson ◽  
Gabor S. Ungvari ◽  
Chuan‑Yue Wang ◽  
...  
Keyword(s):  
Side Effects ◽  
Antipsychotic Treatment ◽  
Extrapyramidal Side Effects

Receptor mechanisms of antipsychotic drug atypicality

1998 ◽  
Vol 13 (S1) ◽  
pp. 5s-8s
Author(s):  
GP Reynolds
Keyword(s):  
Side Effects ◽  
Animal Models ◽  
Negative Symptoms ◽  
Atypical Antipsychotics ◽  
Mechanisms Of Action ◽  
Antipsychotic Treatment ◽  
Extrapyramidal Side Effects ◽  
Treatment Resistant ◽  
Pharmacological Profile ◽  
New Compounds

SummaryRecent advances in antipsychotic treatment of schizophrenia have offered several new compounds which avoid many of the limitations of the classical antipsychotics. These so-called ‘atypical’ antipsychotics have fewer extrapyramidal side effects, greater efficacy against negative symptoms and greater efficacy in otherwise treatment-resistant patients. However, the mechanism of action of these atypical antipsychotics is still unclear. The several receptors currently implicated in the pharmacological profile of these atypical antipsychotics include subtypes of those for dopamine, serotonin, noradrenaline, and acetylcholine among others. The current hypotheses for possible mechanisms of action of atypical antipsychotics are discussed along with the experimental correlates of antipsychotic efficacy in animal models.

CYP2D6 genetic polymorphism and extrapyramidal side effects of antipsychotic drugs

2002 ◽  
Vol 12 ◽  
pp. 266
Author(s):  
B.Kores Plesnicar ◽  
V. Dolzan ◽  
B. Zalar ◽  
M. Tomori ◽  
K. Breskvar
Keyword(s):  
Genetic Polymorphism ◽  
Side Effects ◽  
Antipsychotic Drugs ◽  
Extrapyramidal Side Effects

scholarly journals Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis

2007 ◽  
Vol 191 (S51) ◽  
pp. s88-s95 ◽  
Author(s):  
Stephan Ruhrmann ◽  
Andreas Bechdolf ◽  
Kai-Uwe Kühn ◽  
Michael Wagner ◽  
Frauke Schultze-Lutter ◽  
...  
Keyword(s):  
Side Effects ◽  
Negative Symptoms ◽  
Controlled Study ◽  
Psychotic Symptoms ◽  
Antipsychotic Treatment ◽  
Extrapyramidal Side Effects ◽  
Acute Effects ◽  
Global Functioning ◽  
Prodromal Symptoms ◽  
Symptomatic Benefit

BackgroundPeople in a putatively late prodromal state not only have an enhanced risk for psychosis but already suffer from mental and functional disturbancesAimsTo evaluate the acute effects of a combined supportive and antipsychotic treatment on prodromal symptomsMethodPutatively prodromal individuals were randomly assigned to a needs-focused intervention without (n=59) or with amisulpride (n=65). Outcome measures at 12-weeks effects were prodromal symptoms, global functioning and extrapyramidal side-effectsResultsAmisulpride plus the needs-focused intervention produced superior effects on attenuated and full-blown psychotic symptoms, basic, depressive and negative symptoms, and global functioning. Main side-effects were prolactin associatedConclusionsCoadministration of amisulpride yielded a marked symptomatic benefit. Effects require confirmation by a placebo-controlled study

Monitoring of extrapyramidal side effects in patients on antipsychotic treatment: a completed audit cycle

2015 ◽  
Vol 33 (3) ◽  
pp. 165-169 ◽  
Author(s):  
MI Butler ◽  
J Chandrakanth
Keyword(s):  
Side Effects ◽  
Current Practice ◽  
Antipsychotic Treatment ◽  
Patient Records ◽  
Extrapyramidal Side Effects ◽  
Teaching Session ◽  
Confidence Levels ◽  
Hospital Doctors ◽  
Audit Cycle ◽  
Clinical Records

BackgroundMovement disorders are a common problem in those receiving antipsychotic medication. Clinical guidelines recommend that these side-effects are monitored regularly throughout treatment. However, due to a lack of training, clinician confidence levels in assessment are often low and regular monitoring may be neglected.AimsTo audit current practice in our services regarding monitoring of extrapyramidal side effects (EPSE) and improve monitoring through education of clinicians.MethodThe clinical records of patients receiving antipsychotic treatment, seen in the outpatient clinic over a 2-week period, were reviewed. Data were collected on whether or not EPSE had been assessed. A re-audit was undertaken following a teaching session.ResultsDocumentation regarding EPSE was present in only 14% of patient records. Following a teaching session, the overall level of documentation of EPSE rose to 42%, with rates of assessment dramatically improving in non-consultant hospital doctors.ConclusionIn our practice, clinicians are generally poor to assess and record EPSE. However, rates of assessment improved significantly following a teaching session, especially in NCHDs.

scholarly journals Clozapine-induced intestinal obstruction - a critical examination of four cases

2006 ◽  
Vol 12 (1) ◽  
pp. 4
Author(s):  
C Seller ◽  
L Koen ◽  
D J H Niehaus
Keyword(s):  
Side Effects ◽  
Negative Symptoms ◽  
Critical Examination ◽  
Antipsychotic Treatment ◽  
Extrapyramidal Side Effects ◽  
Atypical Antipsychotic Drug ◽  
Superior Efficacy ◽  
Added Benefit ◽  
Treatment Refractory ◽  
Positive And Negative Symptoms

Clozapine is an atypical antipsychotic drug indicated for the management of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. It has demonstrated superior efficacy in treating both the positive and negative symptoms in treatment-refractory cases. It also has the added benefit of causing minimal extrapyramidal side- effects, producing no tardive dyskinesia and having little effect on prolactin levels

Sign in / Sign up

Export Citation Format

Share Document